Search

Your search keyword '"Rosengarten, Helen"' showing total 24 results
Start Over Author "Rosengarten, Helen"
24 results on '"Rosengarten, Helen"'

16. Animal Models in Tardive Dyskinesia.

Author

Boulton, Alan A., Baker, Glen B., Martin-Iverson, Mathew T., Rosengarten, Helen, Schweitzer, Jack W., and Friedhoff, Arnold J.

Abstract

The introduction of neuroleptics in 1952 to clinical practice was followed by numerous reports in the literature describing a syndrome of abnormal involuntary movements that appeared with increasing frequency during treatment or during withdraw al from neuroleptics. This syndrome was first described in the late 1950s (Hall et al., 1956; Kullenkampf and Tarnow, 1956; Schoenecker, 1957; Sigwald et al., 1959) and these reversible and irreversible drug-related dyskinesias were subsequently named tardive dyskinesia (Uhrband and Faurbye, 1960). The role of neuroleptics as the cause of tardive dyskinesia remained controversial for many years; subsequently, a number of investigators concluded that chronic neuroleptic treatment may precipitate TD only in those patients who are already predisposed to the development of this disorder (Smith and Baldessarini, 1980; Itil et al., 1981; Kane and Smith, 1982; Marsden, 1985; Waddington et al., 1988; Toenniessen et al., 1985; Hanssen et al., 1988). [ABSTRACT FROM AUTHOR]

Published
1991
Full Text
View/download PDF

24. Role of epinephrine stimulation of CNS alpha1-adrenoceptors in motor activity in mice.

Author

Stone EA, Grunewald GL, Lin Y, Ahsan R, Rosengarten H, Kramer HK, and Quartermain D

Subjects
Adrenergic beta-Antagonists pharmacology, Animals, Benzylamines pharmacology, Betaxolol pharmacology, Cell Line, Epinephrine administration & dosage, Epinephrine pharmacology, Humans, Hydrolysis, Imidazoles pharmacology, Injections, Intraventricular, Kidney drug effects, Kidney metabolism, Male, Mice, Norepinephrine pharmacology, Phenylephrine pharmacology, Phosphatidylinositols metabolism, Prazosin pharmacology, Receptors, Adrenergic, alpha drug effects, Serotonin pharmacology, Adrenergic alpha-Agonists pharmacology, Adrenergic alpha-Antagonists pharmacology, Brain drug effects, Epinephrine antagonists & inhibitors, Motor Activity drug effects, Norepinephrine analogs & derivatives, Prazosin analogs & derivatives, Receptors, Adrenergic, alpha metabolism
Abstract

The role of brain epinephrine (EPI) in the regulation of motor activity and movement in mice was examined. Blockade of EPI synthesis with i.p. 2,3-dichloro-alpha-methylbenzylamine (DCMB) or LY134046 was found to produce marked behavioral inactivity which could be significantly reversed by intraventricular injection of EPI and by three other alpha(1)-adrenoceptor agonists, norepinephrine (NE), 6-fluoronorepinephrine (6FNE), and phenylephrine (PE), as well as by serotonin (5HT). EPI had the largest effect of these agonists and also was the only one that reversed nondrug-induced inactivity of mice in their home cages during the light phase. The effects of EPI were blocked by coinfusion of an alpha(1)-adrenoceptor antagonist (terazosin) but not of an alpha(2)-(atipamezole) or beta(1) (betaxolol)-blocker. The rank order of maximal behavioral responses to EPI, 6FNE, and PE in DCMB-treated mice was the same as the rank order of their maximal stimulation of hydrolysis of phosphatidylinositol at cloned alpha(1B)-adrenoceptors in cell culture. On the basis of the above findings and of the central distributions of adrenergic neurons and alpha(1)-adrenoceptors, the existence of a central EPI-innervated alpha(1)-adrenergic receptor system is postulated which serves to coexcite or enhance signaling in several monoaminergic brain regions involved in movement and motor activity., (Copyright 2003 Wiley-Liss, Inc.)

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results